SCHEMBL3787372

SCHEMBL3787372

O=C1NCCN1c1csc2ccncc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.39
SCN9A Q15858 1/20 0.39
CYP17A1 P05093 4/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PRKCH P24723 1/20 0.35
PRKCE Q02156 1/20 0.35
MAPT P10636 4/20 0.35
ALOX5AP P20292 1/20 0.34
FEN1 P39748 1/20 0.34
TP53 P04637 3/20 0.33
LMNA P02545 1/20 0.33
PTGER2 P43116 1/20 0.33
DRD2 P14416 1/20 0.33
DRD3 P35462 1/20 0.33
KCNH2 Q12809 1/20 0.33
THRB P10828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3787562 0.76 CYP17A1 (0.53) CYP2A6SCN9ACYP17A1DRD2DRD3
SCHEMBL3781174 0.71 SCN9A (0.40) SCN9ACYP17A1CYP1A2CYP3A4TSHR
SCHEMBL3787649 0.69 CYP2A6 (0.48) CYP2A6CYP17A1CYP1A2CYP3A4TSHR
SCHEMBL13735561 0.68 CYP17A1 (0.54) CYP17A1
SCHEMBL27955248 0.68 SCN9A (0.40) SCN9ACYP17A1CYP1A2CYP3A4TSHR
SCHEMBL3962397 0.67 CYP2A6 (0.53) CYP2A6SMN1; SMN2MAPTLMNAPIM1
SCHEMBL30940059 0.67 CYP2A6 (0.53) CYP2A6SMN1; SMN2MAPTLMNAPIM1
SCHEMBL3781964 0.66 CYP17A1 (0.52) SCN9ACYP17A1MAPTTP53LMNA
SCHEMBL2960834 0.66 ADRB2 (0.48) CYP1A2CYP3A4TSHRSMN1; SMN2HSD17B10
SCHEMBL1006461 0.66 CYP2A6 (0.56) CYP2A6CYP1A2CYP3A4MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE45173-E1 Inhibitors of CYP 17 NOVARTIS AG (CH) 2014-09-30 US disclosed
US-20140228394-A1 INHIBITORS OF CYP 17 NOVARTIS AG (CH) 2014-08-14 US disclosed
US-8263635-B2 Inhibitors of CYP 17 NOVARTIS AG (CH) 2012-09-11 US disclosed
US-20100331326-A1 Inhibitors of CYP 17 NOVARTIS AG 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331326-A1 Inhibitors of CYP 17 CYP17A1, CYP21A2, CYP4A22 CYP2A6 51/4885SCN9A 2049/4885CYP17A1 1/4885
US-20140228394-A1 INHIBITORS OF CYP 17 CYP17A1, CYP21A2, CYP4A22 CYP2A6 51/4885SCN9A 2049/4885CYP17A1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.